Sam Brusco, Associate Editor08.17.22
Knee osteoarthritis treatment firm Moximed has gained $40 million in Series C equity and debt financing.
Proceeds will be used to gain necessary regulatory approvals and build commercial infrastructure for the company’s MISHA knee system, an implantable shock absorber (ISA) for the knee.
The concept of weight load reduction on diseased joints was used to design MISHA. It’s implanted in an outpatient procedure and has been clinically demonstrated to alleviate pain, improve function, and possibly delay the need for total knee replacement in some patients.
Moximed will share results from its recently finished Calypso pivotal study at the Orthopedic Summit (OSET) in Boston on September 22.
“Once non-surgical care is exhausted, patients suffering from knee OA become very frustrated with the lack of options to address their continued pain and disability. As their surgeon, I share their frustration. When, despite our best medical management efforts, my patients are faced with enduring chronic pain or submitting to early joint replacement, I’m left offering them options that they really don’t want,” Anil Ranawat, M.D., Chief, Hip and Knee Division of Sports Medicine Institute, Hospital for Special Surgery told the press.
“We’ve listened carefully to patients, and their surgeons, and we’re excited to develop a solution that meets their needs,” said Anton Clifford, Ph.D., Moximed CEO. “Patients deserve treatment options that allow them to live life to their fullest abilities, whether it’s caring for a loved one, returning to a favorite sport, or simply getting through their working day. Results from our pivotal study show the MISHA Knee System not only alleviates pain and OA-induced activity limitations, but also offers complete preservation of the knee, an outpatient procedure, and early weight bearing. These are all strong preferences expressed by our patient population.”
Proceeds will be used to gain necessary regulatory approvals and build commercial infrastructure for the company’s MISHA knee system, an implantable shock absorber (ISA) for the knee.
The concept of weight load reduction on diseased joints was used to design MISHA. It’s implanted in an outpatient procedure and has been clinically demonstrated to alleviate pain, improve function, and possibly delay the need for total knee replacement in some patients.
Moximed will share results from its recently finished Calypso pivotal study at the Orthopedic Summit (OSET) in Boston on September 22.
“Once non-surgical care is exhausted, patients suffering from knee OA become very frustrated with the lack of options to address their continued pain and disability. As their surgeon, I share their frustration. When, despite our best medical management efforts, my patients are faced with enduring chronic pain or submitting to early joint replacement, I’m left offering them options that they really don’t want,” Anil Ranawat, M.D., Chief, Hip and Knee Division of Sports Medicine Institute, Hospital for Special Surgery told the press.
“We’ve listened carefully to patients, and their surgeons, and we’re excited to develop a solution that meets their needs,” said Anton Clifford, Ph.D., Moximed CEO. “Patients deserve treatment options that allow them to live life to their fullest abilities, whether it’s caring for a loved one, returning to a favorite sport, or simply getting through their working day. Results from our pivotal study show the MISHA Knee System not only alleviates pain and OA-induced activity limitations, but also offers complete preservation of the knee, an outpatient procedure, and early weight bearing. These are all strong preferences expressed by our patient population.”